about
Peptide-Based Treatment: A Promising Cancer TherapyCompanion diagnostics for the targeted therapy of gastric cancerNeoadjuvant or adjuvant therapy for gastric cancerWhether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patientsFrequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system.Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.Tumor and serum gamma-glutamyl transpeptidase, new prognostic and molecular interpretation of an old biomarker in gastric cancer.Immunohistochemical Expression of Human Epidermal Growth Factor Receptor 2 (HER2) and p53 in Gastric Adenocarcinoma: A Pilot Study from Northern India.Enhanced expression of long non-coding RNA HOTAIR is associated with the development of gastric cancer.Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis.HER2/neu-directed therapy for biliary tract cancer.Correlation between apparent diffusion coefficients and HER2 status in gastric cancers: pilot study.Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country.Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease.Recent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsCisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer.Enhanced expression of semaphorin 3E is involved in the gastric cancer development.Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Targeting HER 2 and angiogenesis in gastric cancer.Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring.Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer.Pharmacokinetic interaction study of combining imatinib with dasatinib in rats by UPLC-MS/MS.Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical OutcomesDownregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin.Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.MiR-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway.Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity.HER2 Overexpression in Retinoblastoma: A Potential Therapeutic Target?Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study.PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer.Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.Metastatic adenocarcinomas of the stomach or esophagogastric junction (UICC stage IV) are not always a palliative situation: a retrospective analysis.Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
P2860
Q26777032-00AA160C-BFF0-43DF-8239-FEEB8324845FQ26780298-6887F7A7-24D3-484E-9B87-85A9E25E5BD8Q26797427-1A958091-C310-45AB-96CD-22AACD78B8E9Q28067696-45B8EE89-A253-49A0-8455-72113044C556Q31112933-957939C7-3126-4B34-B38E-3A50741B57FCQ33626875-7DE3A017-38F7-455B-BF12-82BC3FD70851Q33755476-93BEE271-3EE8-4713-98EE-86553B84C85AQ33829437-E9EE4730-026F-4B56-9A18-89E916D2887EQ33831937-5B6BCEA8-D485-4C93-AA5D-81A5EB753597Q35018720-F10CFEBD-39D2-4B46-B9B3-B4CA6F45202CQ35043734-2F6F1BA6-A34F-4DF6-8924-313C7CF67631Q35538755-34649274-7875-4BB0-B2E0-DC0721DB2CDEQ35748129-42BCE5F6-A2DB-416B-9B8D-8E41FE3AED03Q35815603-3100735E-B4CC-4223-AC0C-B7A5A047B06EQ35949785-54D1F42E-4C16-46C7-800B-14536282649AQ36184699-5D448E65-445A-4D22-A703-E654F455ECC1Q36234315-A66BA10D-9567-483D-9CB8-642F6173C23BQ36273796-269A97EC-B503-4A32-8452-8F1B14C8018DQ36548702-E8A75645-1497-4708-B460-FEF4A1B15922Q37001973-37967D79-3424-4F80-B852-0CC5C5E2AFBAQ37103968-B560E722-63E8-4196-B72E-460922C12F8FQ37580446-AF454984-6DED-4112-9053-305711940BFCQ37708897-AC800212-A1B8-4B32-A651-ABFE312E91CEQ38633308-38F2564B-6348-4E46-B5D1-C970A80495ABQ38646686-E1B72162-F66B-42A9-8EF9-2FC60D70DF78Q39080349-2E84F55A-5A63-4562-8387-42BAB38FB78DQ39183864-61E31BAB-BE70-467C-9C75-7601B8D32EF4Q41297044-DC841448-22AE-4B80-A0B9-9EF4BDFE444BQ41509859-F1A607FF-92BF-4DB2-A0C6-DB4A5082256EQ41992584-B2ACA9CC-1DAF-4C7A-948C-671C00723707Q42290643-45CA4C79-89FF-4A50-B6F7-423FDB6B841FQ47100522-2EE3E337-4A59-4A1D-A001-05BE4ACC1D96Q47107454-B925DC8E-66FA-4D54-B3ED-40DB61713240Q47286758-E73D08D5-1D1A-4055-9183-8B08339BD02BQ47304027-B7CD140D-6B42-40B8-9687-0A41BF82885AQ47678852-9B30EC1E-59E1-486B-B6BE-FF9B0934401CQ47838777-7DE91AEB-13CD-49DE-9751-229791FAB348Q48234912-7E469A77-64E9-4489-AE34-5B40263545D2Q50761729-16D30113-49EC-4B0C-AEE6-A41340BE42D3Q51232753-D8B1B4FF-2EF1-4A7E-AE7B-921FA2193CC7
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HER2-positive gastric cancer.
@en
HER2-positive gastric cancer.
@nl
type
label
HER2-positive gastric cancer.
@en
HER2-positive gastric cancer.
@nl
prefLabel
HER2-positive gastric cancer.
@en
HER2-positive gastric cancer.
@nl
P2860
P921
P1433
P1476
HER2-positive gastric cancer.
@en
P2093
Narikazu Boku
P2860
P2888
P356
10.1007/S10120-013-0252-Z
P577
2013-04-07T00:00:00Z
2014-01-01T00:00:00Z